A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-019-01511-0
Abstract: The efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-PTX) plus gemcitabine (GEM) in elderly Japanese patients with pancreatic cancer remain unclear. Therefore, we prospectively investigated the tolerability and efficacy of nab-PTX + GEM in Japanese patients aged… read more here.
Keywords: nab ptx; pancreatic cancer; efficacy; plus gemcitabine ... See more keywords
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Sign Up to like & getrecommendations! Published in 2021 at "The Lancet"
DOI: 10.1016/s0140-6736(20)32554-x
Abstract: BACKGROUND The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer. METHODS… read more here.
Keywords: high grade; ovarian cancer; plus gemcitabine; cancer ... See more keywords
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003255
Abstract: Background VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor.… read more here.
Keywords: paclitaxel plus; plus gemcitabine; patients advanced; nab paclitaxel ... See more keywords
A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.1082
Abstract: 1082Background: PG chemotherapy is one of the preferred chemotherapeutic regimens for patients with MBC. Eribulin mesylate is a non-taxane inhibitor of microtubule dynamics of the halichondrin class. A recent pooled analysis with eribulin showed improved… read more here.
Keywords: chemotherapy; first line; breast cancer; plus gemcitabine ... See more keywords
Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.11542
Abstract: 11542Background: Olaratumab (O) is an antibody against platelet-derived growth factor receptor alpha. In a randomized phase 2 study, O in combination with doxorubicin (dox) demonstrated a significa... read more here.
Keywords: phase; study olaratumab; olaratumab plus; plus gemcitabine ... See more keywords
Cobimetinib plus gemcitabine is an active combination in KRAS G12R-mutated in previously chemotherapy-treated and failed pancreatic patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.4642
Abstract: 4642Background: he KRAS proto-oncogene is involved in the RAS/MAPK pathway. Various G12X mutations have been examined with the most common mutations being G12D (40%), G12V (30%), and G12R (15-20%) ... read more here.
Keywords: combination kras; cobimetinib plus; active combination; plus gemcitabine ... See more keywords
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Surgery"
DOI: 10.1200/jco.2022.40.4_suppl.387
Abstract: BACKGROUND This study was conducted to evaluate the clinical feasibility of nab-paclitaxel plus gemcitabine-cisplatin triplet chemotherapy in patients with locally advanced cholangiocarcinoma in real-world practice. METHODS We retrospectively reviewed patients with locally advanced cholangiocarcinoma who… read more here.
Keywords: locally advanced; paclitaxel plus; advanced cholangiocarcinoma; plus gemcitabine ... See more keywords